Live Chat

Actos Study Shows 40 Percent Increase in Cancer Risk for Some Patients

According to a study involving nearly 200,000 Actos (pioglitazone) patients, people who were prescribed pioglitazone therapy for longer than 12 months had a forty percent increase in the risk for bladder cancer. Commonly called a “dose-response effect,” this finding revealed that the risk of bladder cancer rose in correlation with the number of doses patients consumed.

 

Tragically, despite the fact that the Food and Drug Administration (FDA) and other members of the medical community have encouraged doctors to use caution when prescribing Actos (pioglitazone), not all medical professionals have followed this warning. In fact, some have continued to prescribe Actos (pioglitazone), despite the fact that patients have had such symptoms as red-colored urine, pain while urinating, and pain in their lower back or lower abdomen. Still, Actos has not been taken off the market. And if you have diabetes, your doctor might have put you on this drug, too.

 

Fears Nachawati attorneys are protecting Actos (pioglitazone) patients from the effects of this dangerous drug. If you’re an Actos (pioglitazone) patient, you ought to talk to our experts to find out if your rights have been violated – and whether you can recover. For your free consultation, call us at 1.866.545.8364 or email mn@fnlawfirm.com

Categories
Drug Litigation

Actos Study Shows 40 Percent Increase in Cancer Risk for Some Patients